Analysts Set Nevro Corp. (NYSE:NVRO) Price Target at $6.43

Nevro Corp. (NYSE:NVRO) has earned an average recommendation of “Reduce” from the thirteen analysts that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $6.43.

NVRO has been the subject of a number of recent research reports. StockNews.com assumed coverage on Nevro in a research report on Sunday. They set a “hold” rating for the company. Wells Fargo & Company decreased their price target on Nevro from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th. Jefferies Financial Group raised shares of Nevro from an “underperform” rating to a “hold” rating and boosted their price objective for the company from $4.50 to $5.85 in a research note on Monday, February 10th. Morgan Stanley downgraded shares of Nevro from an “equal weight” rating to an “underweight” rating and lowered their target price for the company from $9.00 to $4.00 in a report on Monday, December 2nd. Finally, Canaccord Genuity Group increased their price target on shares of Nevro from $4.00 to $5.85 and gave the stock a “hold” rating in a report on Friday, February 7th.

Institutional Investors Weigh In On Nevro

Several institutional investors have recently modified their holdings of the company. Amundi acquired a new position in Nevro during the fourth quarter worth $30,000. Oxford Asset Management LLP acquired a new position in shares of Nevro during the 4th quarter worth $39,000. Corton Capital Inc. acquired a new position in shares of Nevro during the 4th quarter worth $43,000. Headlands Technologies LLC purchased a new stake in shares of Nevro in the 4th quarter worth about $45,000. Finally, Ieq Capital LLC acquired a new stake in Nevro in the 4th quarter valued at about $46,000. Hedge funds and other institutional investors own 95.52% of the company’s stock.

Nevro Stock Up 0.1 %

NVRO stock opened at $5.85 on Friday. The company has a market cap of $224.28 million, a price-to-earnings ratio of -3.09 and a beta of 0.94. The company has a fifty day moving average price of $5.56 and a 200 day moving average price of $4.96. The company has a debt-to-equity ratio of 0.67, a current ratio of 5.02 and a quick ratio of 3.76. Nevro has a 12 month low of $3.17 and a 12 month high of $14.43.

Nevro (NYSE:NVRO) last announced its earnings results on Tuesday, March 4th. The medical equipment provider reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.15. Nevro had a negative net margin of 16.54% and a negative return on equity of 23.52%. The business had revenue of $105.55 million during the quarter, compared to analysts’ expectations of $102.61 million. Sell-side analysts expect that Nevro will post -2.44 earnings per share for the current year.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.